Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | APP | P05067 | 4/20 | 1.00 |
| ▸ | SNCA | P37840 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | RBP4 | P02753 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.80 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.80 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | DRD3 | P35462 | 2/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Retinol SCHEMBL15592 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA | |
| Retinol SCHEMBL1580302 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA | |
| Retinol SCHEMBL3113 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA | |
| Retinol SCHEMBL19660979 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA | |
| Retinol SCHEMBL3112 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA | |
| Retinol SCHEMBL1433566 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA | |
| Zuretinol SCHEMBL254333 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA | |
| Retinol SCHEMBL8360234 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA | |
| Retinol SCHEMBL14619410 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA | |
| Retinol SCHEMBL17226 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731618-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF SELECTIVE TTR LIGAND AND C20-D3-RETINOL | The Trustees Of Columbia University In The City Of New York (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4731619-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF BISPECIFIC RBP4/TTR LIGAND AND C20-D3-RETINOL | The Trustees Of Columbia University In The City Of New York (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4731204-A2 | SELECTIVE RBP4 ANTAGONIST AND C20-D3-RETINOL FOR TREATING MACULAR DEGENERATION, NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), AND GOUTY ARTHRITIS (GOUT) | The Trustees Of Columbia University In The City Of New York (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260042803-A1 | VARIANT AAV CAPSID POLYPEPTIDES TARGETING THE EYE | REVVITY GENE DELIVERY GMBH (DE) | 2026-02-12 | — | — | US | claimed |
| EP-4626260-A2 | FERMENTATIVELY-PRODUCED RETINOID CONTAINING COMPOSITIONS, AND THE METHDOS OF MAKING AND USING THE SAME | DSM IP Assets B.V. (NL) | 2025-10-08 | — | — | EP | claimed |
| US-20250305024-A1 | RELATIVE POTENCY ASSAY FOR VIRAL VECTOR ENCODING ISOMEROHYDROLASES | SPARK THERAPEUTICS, INC. | 2025-10-02 | — | — | US | claimed |
| US-12359239-B2 | Relative potency assay for viral vector encoding isomerohydrolases | SPARK THERAPEUTICS, INC. (US) | 2025-07-15 | — | — | US | claimed |
| WO-2024263751-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF SELECTIVE TTR LIGAND AND C20-D3-RETINOL FOR ELIMINATION OF MECHANISM-BASED OCULAR ADVERSE EFFECTS IN TREATING MACULAR DEGENERATION AND TTR AMYLOIDOSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-12-26 | — | — | WO | claimed |
| WO-2024263790-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF SELECTIVE RBP4 ANTAGONIST AND C20-D3-RETINOL FOR ELIMINATION OF MECHANISM-BASED OCULAR ADVERSE EFFECTS IN TREATING MACULAR DEGENERATION, NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), AND GOUTY ARTHRITIS (GOUT) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-12-26 | — | — | WO | claimed |
| WO-2024263782-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF BISPECIFIC RBP4/TTR LIGAND AND C20-D3-RETINOL FOR ELIMINATION OF MECHANISM-BASED OCULAR ADVERSE EFFECTS IN TREATING MACULAR DEGENERATION AND TTR AMYLOIDOSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-12-26 | — | — | WO | claimed |
| EP-1624853-A2 | SKIN TREATMENTS | Unilever Plc (GB) | 2006-02-15 | — | — | EP | claimed |
| CN-1704469-A | Method for producing Chinese aweto fungus | SHEN NANYING (CN) | 2005-12-07 | — | — | CN | claimed |
| US-20050002879-A1 | External skin compositions | KAO CORPORATION (JP) | 2005-01-06 | — | — | US | claimed |
| WO-2004103320-A2 | SKIN TREATMENTS | UNILEVER PLC (GB) | 2004-12-02 | — | — | WO | claimed |
| EP-0824348-B1 | TREATMENT OF PSORIASIS WITH 11-CIS-RETINOIC ACID | BRAIMAN MARK S (US) | 2002-09-11 | — | — | EP | claimed |
| CN-1063788-C | Fermenting production process of cordyceps fungus | SHEN NANYING (CN) | 2001-03-28 | — | — | CN | claimed |
| WO-1999016783-A1 | POTENT INHIBITORS OF HUMAN 9-CIS RETINOL DEHYDROGENASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1999-04-08 | — | — | WO | claimed |
| CN-1197843-A | Fermenting production process of Cordyceps fungus | SHEN NANYING (CN) | 1998-11-04 | — | — | CN | claimed |
| EP-0824348-A1 | TREATMENT OF PSORIASIS WITH 11-CIS-RETINOIC ACID | BRAIMAN, Mark S. (US) | 1998-02-25 | — | — | EP | claimed |
| US-5719195-A | Treatment of psoriasis with 11-cis-retinoic acid | 4 THOUGHT TECHNOLOGIES (US) | 1998-02-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042803-A1 | VARIANT AAV CAPSID POLYPEPTIDES TARGETING THE EYE | UPF1, VEGFA, PRNP | ALDH1A1 4293/4885MAPT 492/4885CYP3A4 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.